Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
LeukemiaLymphomaMyeloma
Interventions
DRUG

Busulfan

Day -10 = 32 mg/m\^2 Intravenous Test Dose; Days -8 thru -5 = 105 mg/m\^2 Intravenous

DRUG

Gemcitabine

Day -8 = 75 mg/m\^2 Intravenous bolus; Day -3 = 75 mg/m\^2 Intravenous bolus.

DRUG

Melphalan

Day -3 and Day -2 = 60 mg/m\^2 Intravenous.

OTHER

Hematopoietic Cell Transplantation

Infusion of stem cells on Day 0.

DRUG

Rituximab for Patients with B-Cell Malignancies

375 mg/m\^2 Intravenous on Days 1 and 8.

DRUG

Palifermin

60 microgram/kg by vein on Days -13 to -11 and Days 0, +1, +2

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00410982 - Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies | Biotech Hunter | Biotech Hunter